title: Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen.
authors.forename: G A
authors.initials: GA
authors.lastname: Kennedy
authors.forename: S
authors.initials: S
authors.lastname: Durrant
authors.forename: J
authors.initials: J
authors.lastname: Butler
authors.forename: J
authors.initials: J
authors.lastname: Morton
authors.forename: R
authors.initials: R
authors.lastname: Western
authors.forename: M L
authors.initials: ML
authors.lastname: Bartlett
authors.forename: R
authors.initials: R
authors.lastname: Allison
authors.forename: D J
authors.initials: DJ
authors.lastname: MacFarlane
mesh_terms: D000328:Adult; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy*; D009942:Organometallic Compounds / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D011868:Radioisotopes / Q000627:therapeutic use*; D011877:Radionuclide Imaging; D015203:Reproducibility of Results; D012493:Samarium / Q000627:therapeutic use*; D013997:Time Factors; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D011868:Radioisotopes; D012493:Samarium; C061972:samarium Sm-153 lexidronam